VC and Investment
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Today's issue
Refine Search
Biotechnology
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Biotechnology
Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with participation from new investors Sanofi and Invus 25 October 2024
Pharmaceutical
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
Biotechnology
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024
Biotechnology
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
Pharmaceutical
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
Pharmaceutical
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
Pharmaceutical
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Biotechnology
In Cambridge, UK, the protein specialist Nuclera has raised $75 million in a funding round led by Elevage Medical Technologies and backed by Patient Square Capital. 16 October 2024
Biotechnology
Tolerance Bio has announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners. 16 October 2024
Biotechnology
In Hong Kong, Akeso Biopharma has successfully raised $250 million through a share placement, marking its second major fundraising effort of 2024. 15 October 2024
Pharmaceutical
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Biotechnology
Boston, USA-based Upstream Bio, a biotech developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, has made an impressive start to life as a public-listed company.00000 14 October 2024
Pharmaceutical
Skyepharma’s underlying business is strong now the company has repaid bonds and other costly loans, according to a new report from Edison Investment Research. 18 May 2015
Biotechnology
Privately-held Moderna Therapeutics, a specialist in messenger RNA, has launched Elpidera LLC, a new venture focused solely on the advancement of mRNA-based medicines for rare diseases. 12 May 2015
Pharmaceutical
Spanish pharma company Zeltia is laying the groundwork for a period of significant potential growth and value creation, according to a report from investment research company Edison, which has raised its valuation. 18 March 2015
Pharmaceutical
UK pharma major GlaxoSmithKline says that it plans to dispose of half its current 12.4% stake in South African drugmaker Aspen Pharmacare. 13 March 2015
Biotechnology
The Bill & Melinda Gates Foundation has committed to invest $52 million in private biopharma company CureVac, the biggest equity investment the Foundation has ever made in a biotech company. 6 March 2015
Pharmaceutical
The proposed bonus for Olivier Brandicourt, the new chief executive of Sanofi has drawn criticism from government and trade unions. 25 February 2015
Biotechnology
Biotech firm SOBI has reported its fourth quarter and full-year 2014 financial results showing a loss. 19 February 2015
Pharmaceutical
Three former pharma and health care executives have formed a new partnership to provide strategic support to pharma companies in identifying and leveraging revenue opportunities. 18 February 2015
Pharmaceutical
Nutrinia, a developer of oral insulin therapies to treat rare gastrointestinal disorders in babies, has successfully completed a $12 million round of funding. 18 December 2014
Generics
Belgian drugmaker UCB and private equity firms Avista Capital and Advent International have mutually agreed to terminate an agreement whereby UCB would have divested its specialty generics unit Kremers Urban Pharmaceuticals to the private equity firms for $1.5 billion. 17 December 2014
Biotechnology
UK-based antibody therapeutics specialist Crescendo Biologics has received another equity investment from Astellas Venture Management to support the discovery and development of new Humabody antibody fragment therapeutics in oncology. 16 December 2014
Pharmaceutical
Following AbbVie’s recent abandonment of a $53 billion takeover offer, Ireland-headquartered drugmaker Shire (LSE: SHP) has announced it is to relocate more than 500 positions from Chesterbrook, Pennsylvania to Massachusetts. 19 November 2014
Pharmaceutical
The chief executive of the capital management company assisting Valeant Pharmaceuticals in its attempts to purchase Allergan urged it to initiate an open sale process as reports emerged that the company had entered negotiations with Actavis. 10 November 2014
Biotechnology
Biotech firm Swedish Orphan Biovitrum has announced total revenues of 665.9 million Swedish kronor ($99.8 million) for the third quarter of 2014, an increase of 25.2% on figures from the same period last year. 30 October 2014
Pharmaceutical
Botox maker Allergan has reported strong quarterly results amid an ongoing buyout dispute with Quebecois pharma company Valeant. 27 October 2014
Pharmaceutical
US-based pharma company Reckitt Benckiser Pharmaceuticals announced that its UK-based parent company, Reckitt Benckiser Group will complete the proposed demerger of the pharma business to complete this year. 21 October 2014
Biotechnology
Norgine Ventures, the business entity of privately-owned European pharma company Norgine, has provided financing of up to 7 million euros to Danish specialty pharma company Azanta Danmark in an investment to help it fund its late-stage clinical development pipeline and grow commercial sales. 13 October 2014
Pharmaceutical
Pershing Square Capital Management, the largest shareholder of Allergan, which is the subject of a $53 billion hostile acquisition approach by Canada’s Valeant Pharmaceuticals International (The Pharma Letters passim), announced on Friday that it submitted the required documentation to compel Allergan to call a special meeting of its shareholders. 23 August 2014
Pharmaceutical
While speculation continues as to whether Pfizer will resume its attempts to buy AstraZeneca, Pfizer is reportedly looking to buy Ireland-headquartered generics major Actavis, according to sources close to the companies quoted by Bloomberg. 22 August 2014
Pharmaceutical
Allergy specialist Allergan has appointed Jim Hindman as chief financial officer, effective immediately, replacing Jeff Edwards. 19 August 2014
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze